Copyright
©The Author(s) 2015.
World J Gastroenterol. Oct 7, 2015; 21(37): 10604-10608
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10604
Published online Oct 7, 2015. doi: 10.3748/wjg.v21.i37.10604
Table 1 Substaging of intermediate-stage; Bolondi substaging system
Intermediatesubstage | B1 | B2 | B3 | B4 |
Child-Pugh score | 5-7 | 5-6 | 7 | 8-9 |
Up-to-7 criterion | In | Out | Out | Any |
1st option | TACE | TACE or TARE | BSC | |
Alternative | LT | Sorafenib | Research trial | LT |
TACE + Ablation | TACE | |||
Sorafenib | ||||
Median survival time (mo) | 41.0 | 22.1 | 14.1 | 17.2 |
Table 2 Substaging of intermediate-stage; proposal from japanese society of transcatheter hepatic arterial embolization
Intermediate-substage | B1 | B2 | B3 |
Child-Pugh score | 5-6 | 5-8 | 9 |
4-of-7 cm criterion | In | In (CP 7-8) | Any |
or | |||
Out (CP 5-8) | |||
2-yr survival rate | 77.2% | 59.5% | 16.7% |
Median survival time (mo) | 40.5 | 28.1 | 13.0 |
- Citation: Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol 2015; 21(37): 10604-10608
- URL: https://www.wjgnet.com/1007-9327/full/v21/i37/10604.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i37.10604